Overcoming Resistance in CNS Lymphoma: Dual Inhibition Approach

Dr. Grzegorz Nowakowski of Mayo Clinic discusses advancements in treating CNS lymphoma, focusing on B-cell receptor-driven disease with MYD88 mutations. While BTK inhibitors show moderate efficacy, resistance remains a challenge. The TakeAim study explores dual inhibition with BTK and IRAK4 inhibitors, showing promising responses in refractory patients. More data is needed, but early results suggest this approach could enhance treatment outcomes.